Sundrug Co. Ltd. said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥36.85 per share, a decrease from ¥37.72 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥4.46 billion, a decrease of 6.3% from ¥4.75 billion in the prior-year period.

The normalized profit margin dropped to 3.9% from 4.1% in the year-earlier period.

Total revenue declined on an annual basis to ¥113.04 billion from ¥116.77 billion, and total operating expenses fell year over year to ¥106.08 billion from ¥109.42 billion.

Reported net income increased 39.6% year over year to ¥4.37 billion, or ¥36.14 per share, from ¥3.13 billion, or ¥24.83 per share.

For the year, the company's normalized net income totaled ¥135.14 per share, a decrease of 5.3% from ¥142.70 per share in the prior year.

Normalized net income was ¥16.57 billion, a decline of 7.9% from ¥17.99 billion in the prior year.

Full-year total revenue totaled ¥445.82 billion, compared with ¥447.82 billion in the prior year, and total operating expenses totaled ¥419.89 billion, compared with ¥419.76 billion in the year-earlier period.

The company said reported net income increased on an annual basis to ¥16.36 billion, or ¥133.48 per share, in the full year, from ¥15.75 billion, or ¥124.98 per share.

As of June 22, US$1 was equivalent to ¥123.23.